Open original FDA record ↗Recall record
- FDA identifier
- Z-2770-2017
- Company in FDA record
- Biomerieux Inc
- FDA classification date
- Jun 27, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
The investigation demonstrated a high rate of very major errors (resistant isolates calling susceptible) with the VITEK 2 AST-GN colistin (cs01n) compared to agar dilution (the reference method used for cs01n development) and compared to broth-microdilution (recommended method by EUCAST/CLSI).
Source facts
- Action
- Customers were notified on or about 05/16/2017 and then notified again with an updated letter. Instructions to customers included requesting that the attached acknowledgement form be completed, distribute the recall notification to customers, and provide the notice to future customers.
- Initiated
- 2017-05-16
- Root cause
- Other
- Terminated
- 2019-06-19
- Distribution
- Domestic: NC. Foreign: Argentina, Austria, Brazil, Canada, Chile, China, Colombia, Costa Rica, Dominican Republic, Ecuador, France, Germany, Guatemala, Hong Kong, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Netherlands Antilles, Nicaragua, Panama, Paraguay, Peru, Philippines, Poland, Singapore, South Africa, South Korea, Spain, Thailand, Turkey, United Kingdom, Uruguay, Venezuela, & Vietnam.
- Recall number
- Z-2770-2017
- Recall status
- Terminated
- CDRH record ID
- 155857
- FDA classified
- 2017-06-27
- Recall event number
- 77373